Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has shared an announcement.
Guangzhou Innogen Pharmaceutical Group Co., Ltd. has announced the completion of the first patient dosing in its Phase III clinical trial for Efsubaglutide Alfa, a core product aimed at treating obesity and overweight conditions in China. This development marks a significant step in the company’s efforts to address these prevalent health issues, with plans to enroll approximately 800 participants in the trial. The outcome of this trial could enhance the company’s market position in the pharmaceutical industry, although there is no guarantee of successful development or marketing of the product.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in the People’s Republic of China, focusing on the development of treatments for obesity and overweight conditions. The company is engaged in clinical trials to bring innovative healthcare solutions to the market.
Average Trading Volume: 1,219,064
For a thorough assessment of 2591 stock, go to TipRanks’ Stock Analysis page.